COVID-19 Vaccine Trials: Reality Check

COVID-19 Vaccine Trials: Reality Check Posted By:
...

There is both good and bad news with respect to the ongoing COVID-19 vaccine trials. As a preface, know that approximately 90% of vaccine trials fail to lead to production of a final vaccine, and 50% of those failures occur in phase 3. Usually, vaccine trials enroll a only few thousand participants who are followed for at least 5 years—observing for adverse events (AEs), efficacy, and durability. AEs usually, but not always, are revealed within the first 2 months of vaccine administration. These are just a few reasons why the COVID-19 vaccine trials are enrolling 30,000+ patients, largely intending to power the trials for efficacy and AEs.

The US has a robust cadre of COVID-19 vaccine trials from 18 different biopharmaceutical companies, three of which are currently in phase 3. A total of 179 vaccines are in development worldwide.

The vaccine being developed jointly by Pfizer and BioNTech is one of three vaccines in phase 3 trials—those being developed by Moderna and AstraZeneca/University of Oxford are the others. Both Pfizer/BioNTech and Moderna are utilizing completely new mRNA technology. Outside study groups have just released interim analyses of these two vaccines, and efficacy appears to be on the order of 95%—far higher than originally hoped for. If born out in subsequent analyses, this is encouraging news.

While exciting, remaining questions should temper enthusiasm. No data have been released; only press releases. And while the efficacy is impressive, it is preliminary and must be confirmed with subsequent analysis. These vaccines were only tested in adults, and the trials did not study children or adults with immunodeficiencies, so no conclusions can be drawn about these and other special populations. Although AEs were generally minor, it has not yet been 2 months since all participants received both doses, so the jury is still out on AEs. And durability—how long the vaccine might provide protection—remains unknown.

There is also a reality regarding the Pfizer vaccine that is often overlooked: it must be stored at extremely low temperatures, -94°F, making the logistics of transportation and administration problematic, at best. This implies that your neighborhood Walgreens may not be able to administer the vaccine, simply because they do not have the cold-storage capability. Thus Pfizer's vaccine may be only for those near major medical centers in densely populated cities. The good news is that the Moderna vaccine is stored at -4°F, making logistics similar to many other vaccines.

There is one very big question that has yet to be answered: Will people get a COVID-19 vaccine? Surveys show the number of Americans answering in the affirmative are dwindling. A Pew Research study published in mid-September reported dismal numbers, with only 51% of US adults saying they definitely or probably would get a COVID-19 vaccine, and 49% saying they definitely or probably would not. Just 32% of Black adults said they would definitely or probably get a COVID-19 vaccine. This bodes poorly for any COVID-19 vaccine and broad population immunity.

References

Share

Filed under: Infectious Diseases , Preventive Medicine , Public Health , Allergy/Immunology

Related
A Major Change in Asthma Management – Is This the Beginning of the End for SABAs?

A Major Change in Asthma Management – Is This th ...

The most recent updated Global Initiative for Asthma (GINA) guidelines recommend that short-acting ...

Filed under: Preventive Medicine, Pulmonary Medicine, NPs & PAs, Allergy/Immunology


Continue Reading
Phenotyping Patients With Severe Asthma: Check Those Biomarkers!

Phenotyping Patients With Severe Asthma: Check Tho ...

Asthma affected approximately 262 million people globally in 2019, and an estimated 5% to 10% of the ...

Filed under: Allergy/Immunology


Continue Reading
Improving Atopic Dermatitis Care

Improving Atopic Dermatitis Care

Facilitating Improvements in Transitions of Care in AD ManagementAtopic dermatitis (AD) is a chronic ...

Filed under: Dermatology, NPs & PAs, Allergy/Immunology


Continue Reading
Trigger Avoidance as a Basic Element in Atopic Dermatitis Management

Trigger Avoidance as a Basic Element in Atopic Der ...

Atopic dermatitis (AD) is a chronic inflammatory disorder affecting millions of pediatric patients ...

Filed under: Dermatology, NPs & PAs, Allergy/Immunology


Continue Reading
Navigating Challenges in the Implementation of Early Peanut Introduction Guidelines

Navigating Challenges in the Implementation of Ear ...

In 2017, the National Institute of Allergy and Infectious Diseases (NIAID) released guidelines advoc ...

Filed under: NPs & PAs, Allergy/Immunology


Continue Reading
JAK Inhibitors for the Management of Atopic Dermatitis

JAK Inhibitors for the Management of Atopic Dermat ...

Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease estimated to affect up to ...

Filed under: Allergy/Immunology, Dermatology


Continue Reading